JP2008543854A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008543854A5 JP2008543854A5 JP2008517028A JP2008517028A JP2008543854A5 JP 2008543854 A5 JP2008543854 A5 JP 2008543854A5 JP 2008517028 A JP2008517028 A JP 2008517028A JP 2008517028 A JP2008517028 A JP 2008517028A JP 2008543854 A5 JP2008543854 A5 JP 2008543854A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- ester
- salt
- cooh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 11
- 150000002148 esters Chemical class 0.000 claims 8
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 125000002686 geranylgeranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 125000002009 alkene group Chemical group 0.000 claims 2
- 150000002016 disaccharides Chemical class 0.000 claims 2
- 125000003827 glycol group Chemical group 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 150000002772 monosaccharides Chemical class 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 229940121649 protein inhibitor Drugs 0.000 claims 2
- 239000012268 protein inhibitor Substances 0.000 claims 2
- 150000004671 saturated fatty acids Chemical class 0.000 claims 2
- 238000012385 systemic delivery Methods 0.000 claims 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/151,174 US8338648B2 (en) | 2004-06-12 | 2005-06-13 | Topical compositions and methods for epithelial-related conditions |
| PCT/US2006/023022 WO2006135894A1 (en) | 2005-06-13 | 2006-06-13 | Compositions and methods for treating inflammatory conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008543854A JP2008543854A (ja) | 2008-12-04 |
| JP2008543854A5 true JP2008543854A5 (enExample) | 2009-07-30 |
Family
ID=37532638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008517028A Pending JP2008543854A (ja) | 2005-06-13 | 2006-06-13 | 炎症状態を治療するための組成物および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US8338648B2 (enExample) |
| EP (1) | EP1899480A4 (enExample) |
| JP (1) | JP2008543854A (enExample) |
| CA (1) | CA2611500A1 (enExample) |
| WO (1) | WO2006135894A1 (enExample) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8338648B2 (en) * | 2004-06-12 | 2012-12-25 | Signum Biosciences, Inc. | Topical compositions and methods for epithelial-related conditions |
| US20060269507A1 (en) * | 2005-05-27 | 2006-11-30 | Susan Fuller | Topical ointment compostion and method for making the same |
| US20070092571A1 (en) * | 2005-10-25 | 2007-04-26 | Schur Henry B | Non-irritating formulation and method for the intradermal delivery of substances |
| US20070166273A1 (en) * | 2006-01-19 | 2007-07-19 | Krivulka Joseph J | Skin treatment educational kit |
| KR100941854B1 (ko) * | 2006-09-01 | 2010-02-11 | (주)아모레퍼시픽 | 오메가-3 지방산을 함유하는 피부 외용제 조성물 |
| US20080138417A1 (en) * | 2006-11-22 | 2008-06-12 | Charles Grigsby | Topical Composition And Method Of Forming |
| JP4300370B2 (ja) | 2007-03-13 | 2009-07-22 | 春三 小林 | 上皮改善剤 |
| US20120141576A1 (en) * | 2007-03-15 | 2012-06-07 | Benjamin Johnson | Treatment of Dermatologic Skin Disorders |
| US20080242741A1 (en) * | 2007-03-30 | 2008-10-02 | Wayne Jeffrey Perry | Intranasal drug delivery system |
| US20080241290A1 (en) * | 2007-03-30 | 2008-10-02 | Wayne Jeffrey Perry | Sinus relief composition and method of producing the same |
| US20130115320A1 (en) | 2007-03-30 | 2013-05-09 | Dynova Laboratories, Inc. | Therapeutic agent for intranasal administration and method of making and using same |
| US20090053319A1 (en) * | 2007-08-21 | 2009-02-26 | Wayne Jeffrey Perry | Sore Throat Relief Composition And Method of Producing Same |
| US20090069446A1 (en) * | 2007-09-06 | 2009-03-12 | Wayne Jeffrey Perry | Dendritic salt therapeutic agent delivery system |
| US20090069433A1 (en) * | 2007-09-10 | 2009-03-12 | Wayne Jeffrey Perry | Nasal rinse additive |
| US20090130232A1 (en) * | 2007-11-20 | 2009-05-21 | Mohammed Zahra | Composition and method for treatment of oral inflammation an ulceration |
| BRPI0819976A2 (pt) * | 2007-12-03 | 2019-02-12 | Signum Biosciences, Inc. | composto mimético de ácido para a inibição de isoprenil-s-cisteinil metiltransferase, composição compreedendo os mesmos, bem como uso dos ditos compostos. |
| US20110053901A1 (en) * | 2008-02-14 | 2011-03-03 | Signum Biosciences, Inc. | Acetyl mimic compounds for the inhibition of isoprenyl-s-cysteinyl methyltransferase |
| WO2009108713A2 (en) * | 2008-02-25 | 2009-09-03 | Signum Biosciences, Inc. | Topical compositions and methods utilizing peptides containing lipid-modified cysteine-containing peptides |
| CN102209701B (zh) * | 2008-11-11 | 2014-10-15 | 西格纳姆生物科学公司 | 异戊二烯基化合物和其方法 |
| US8461204B2 (en) | 2008-11-11 | 2013-06-11 | Signum Biosciences, Inc. | Cysteinyl compounds, compositions and methods of use |
| CN104610109A (zh) * | 2009-11-12 | 2015-05-13 | 西格纳姆生物科学公司 | 抗细菌剂及其组合物 |
| WO2011109505A2 (en) * | 2010-03-02 | 2011-09-09 | Mankovitz Roy J | Non-toxic and environmentally compatible photo-protective preparations |
| US8685309B2 (en) * | 2010-04-26 | 2014-04-01 | The Procter & Gamble Company | Method for making a personal care product |
| US20130123365A1 (en) * | 2010-07-08 | 2013-05-16 | Ramot At Tel-Aviv University Ltd. | Use of fts and analogs to treat non-autoimmune-allergic and non-allergic inflammatory conditions |
| EP2590639A1 (en) * | 2010-07-08 | 2013-05-15 | Ramot at Tel-Aviv University Ltd | Treatment of delayed cutaneous hypersensitivity conditions with s-farnesylthiosalicylic acid and analogs thereof |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| US8183227B1 (en) | 2011-07-07 | 2012-05-22 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
| US8168611B1 (en) | 2011-09-29 | 2012-05-01 | Chemo S.A. France | Compositions, kits and methods for nutrition supplementation |
| KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
| CN104853753A (zh) * | 2012-09-14 | 2015-08-19 | 伊丽莎白·雅顿公司 | 包含艾地苯醌、n-乙酰基-s-法呢基-l-半胱氨酸和麦角硫因的制剂及其用途 |
| US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
| EP2938324B1 (en) * | 2012-12-31 | 2023-11-08 | JRX Biotechnology, Inc. | Liquid topical pharmaceutical nano-emulsion formulations |
| JP2016504050A (ja) | 2013-01-17 | 2016-02-12 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 細胞表現型の改変のためのシグナルセンサーポリヌクレオチド |
| US10639439B2 (en) | 2013-01-30 | 2020-05-05 | Midwest Pharmaceuticals, Llc | Smokeless THC and administration method thereof |
| US10682370B2 (en) * | 2013-03-13 | 2020-06-16 | Nal Pharmaceutical Group Limited | Topical antiviral composition containing a local anesthetic and method of making the same |
| WO2014159813A1 (en) | 2013-03-13 | 2014-10-02 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| US10517817B2 (en) | 2013-05-09 | 2019-12-31 | Syk Technologies, Llc | Deep topical systemic nitric oxide therapy apparatus and method |
| US9078853B2 (en) | 2013-06-18 | 2015-07-14 | Cmpd Licensing, Llc | Dry pharmaceutical compositions for topical delivery of oral medications, nasal delivery and to treat ear disorders |
| RU2557894C2 (ru) * | 2013-10-18 | 2015-07-27 | Общество с ограниченной ответственностью "Фарма Ген" (ООО "Фарма Ген") | Косметическое средство для быстрого восстановления кожи |
| WO2016014722A1 (en) * | 2014-07-22 | 2016-01-28 | Signum Nutralogix, Inc. | Natural extracts for modulating pp2a methylation, and providing antioxidant and anti infalammatory activity |
| US10172786B2 (en) * | 2014-12-16 | 2019-01-08 | Axim Biotechnologies, Inc. | Oral care composition comprising cannabinoids |
| EP3349717A4 (en) | 2015-09-17 | 2019-04-17 | JRX Biotechnology, Inc. | APPROACHES TO IMPROVE SKIN HYDROGENATION OR HUMIDIFICATION |
| EP3454827B1 (en) | 2016-05-12 | 2021-11-24 | Unilever IP Holdings B.V. | Method for stabilizing retinoic acid precursors and a skin benefit composition with stabilized retinoic acid precursors |
| CN109640930B (zh) | 2016-08-19 | 2021-11-26 | 联合利华知识产权控股有限公司 | 抗微生物组合物 |
| BR112019003273B1 (pt) | 2016-08-19 | 2022-04-12 | Unilever Ip Holdings B.V. | Composição antimicrobiana sinérgica |
| US10525025B2 (en) | 2016-11-17 | 2020-01-07 | Cmpd Licensing, Llc | Compounded compositions and methods for treating pain |
| US11986448B2 (en) | 2016-11-17 | 2024-05-21 | Cmpd Licensing, Llc | Compounded compositions and methods for treating pain |
| US10966946B2 (en) | 2016-11-17 | 2021-04-06 | Cmpd Licensing, Llc | Compounded compositions and methods for treating pain |
| US9999604B2 (en) | 2016-11-17 | 2018-06-19 | Cmpd Licensing, Llc | Compounded solutions of diclofenac and lidocaine and methods |
| US11737975B2 (en) | 2016-11-17 | 2023-08-29 | Cmpd Licensing, Llc | Compounded compositions and methods for treating pain |
| US20210161870A1 (en) | 2017-06-07 | 2021-06-03 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
| US12042487B2 (en) | 2018-11-16 | 2024-07-23 | Arcutis Biotherapeutics, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
| US9895359B1 (en) | 2017-06-07 | 2018-02-20 | Arcutis, Inc. | Inhibition of crystal growth of roflumilast |
| US11129818B2 (en) | 2017-06-07 | 2021-09-28 | Arcutis Biotherapeutics, Inc. | Topical roflumilast formulation having improved delivery and plasma half life |
| US12011437B1 (en) | 2017-06-07 | 2024-06-18 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
| US20200155524A1 (en) | 2018-11-16 | 2020-05-21 | Arcutis, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
| US10716758B2 (en) * | 2018-04-09 | 2020-07-21 | Southwest Research Institute | Liposomal statin formulation |
| WO2019226548A1 (en) * | 2018-05-22 | 2019-11-28 | Weinberg Assa | Methods for prevention and treatment of urogenital atrophy of menopause by contact vasodilators |
| JP7492918B2 (ja) | 2018-06-04 | 2024-05-30 | アーキュティス・バイオセラピューティクス・インコーポレーテッド | ロフルミラスト皮膚浸透ラグタイムを改善する方法及び配合物 |
| EP4255393B1 (en) | 2020-12-04 | 2025-05-28 | Arcutis Biotherapeutics, Inc. | Topical roflumilast formulation having antifungal properties |
| CA3242322A1 (en) | 2021-12-28 | 2023-07-06 | Arcutis Biotherapeutics, Inc. | Topical roflumilast aerosol foams |
| AU2023342481A1 (en) | 2022-09-15 | 2025-04-10 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug |
| CN118217280B (zh) * | 2024-01-30 | 2024-09-17 | 青岛农业大学 | 瑞香素在防治碳青霉烯耐药肠杆菌的药物组合物中的应用 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4294852A (en) * | 1973-11-01 | 1981-10-13 | Johnson & Johnson | Skin treating compositions |
| US4380549A (en) * | 1975-07-23 | 1983-04-19 | Scott Eugene J Van | Topical treatment of dry skin |
| PH18373A (en) * | 1982-02-02 | 1985-06-13 | Unilever Nv | Skin treatment composition |
| US4478853A (en) * | 1982-05-17 | 1984-10-23 | S. C. Johnson & Son, Inc. | Skin conditioning composition |
| US4552872A (en) * | 1983-06-21 | 1985-11-12 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing corticosteroids |
| US5019569A (en) | 1986-11-03 | 1991-05-28 | Ortho Pharmaceutical Corporation | Reversal of glucocorticoid-induced skin atrophy |
| US5188826A (en) * | 1988-02-08 | 1993-02-23 | Insite Vision Incorporated | Topical ophthalmic suspensions |
| US5521215A (en) | 1989-11-07 | 1996-05-28 | Ramot University Authority For Applied Research And Industrial Development Ltd. | NMDA-blocking pharmaceuticals |
| US5284867A (en) | 1989-11-07 | 1994-02-08 | Yissum Research Development Company Of The Hebrew University In Jerusalem | NMDA-blocking pharmaceutical compositions |
| US5043268A (en) * | 1990-05-04 | 1991-08-27 | The Trustees Of Princeton University | Substrates and inhibitors for prenyl cysteine methyltransferase enzymes |
| US6096740A (en) | 1990-11-06 | 2000-08-01 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions |
| TW198008B (enExample) | 1991-04-08 | 1993-01-11 | Green Cross Corp | |
| US5310545A (en) * | 1991-04-11 | 1994-05-10 | Drore Eisen | Method of treatment using mouthwashes containing steroids and antifungal agents and compositions of matter |
| US5202456A (en) | 1991-04-15 | 1993-04-13 | The President And Fellows Of Harvard College | Compounds for inhibition of protein methylation |
| US5451700A (en) | 1991-06-11 | 1995-09-19 | Ciba-Geigy Corporation | Amidino compounds, their manufacture and methods of treatment |
| JP2636118B2 (ja) * | 1991-09-10 | 1997-07-30 | 三省製薬株式会社 | 育毛剤 |
| WO1994001126A1 (en) | 1992-07-14 | 1994-01-20 | President And Fellows Of Harvard College | Compounds for inhibition of proteolysis |
| US5455274A (en) | 1992-12-09 | 1995-10-03 | Ciba-Geigy Corporation | Hydroxyamidine derivatives |
| US5482710A (en) | 1993-07-30 | 1996-01-09 | Chesebrough-Pond'usa Co., Division Of Conopco, Inc. | Cosmetic composition for treatment of pimples and redness |
| US5567729A (en) * | 1993-10-28 | 1996-10-22 | David L. Bradfute | Farnesyl compounds as farnesyl protein transferase inhibitors to treat ras induced tumor growth |
| IL107587A (en) | 1993-11-12 | 1998-08-16 | Univ Ramot | Farnesyl geranyl or geranyl-geranyl derivatives pharmaceutical compositions containing them and methods for their preparation |
| US5470882A (en) | 1994-06-02 | 1995-11-28 | Smithkline Beecham Corp. | Anti-inflammatory compounds |
| US5571687A (en) | 1994-06-07 | 1996-11-05 | Duke University | Modulators of multidrug resistance transporters |
| WO1995034303A1 (en) * | 1994-06-13 | 1995-12-21 | Arcturus Pharmaceutical Corporation | Method for the treatment, prevention or minimization of hair loss |
| US5658881A (en) * | 1994-10-14 | 1997-08-19 | Twk, Inc. | Method for topical inhibition of the metabolic activity of cytochrome P450 |
| FR2727117A1 (fr) | 1994-11-18 | 1996-05-24 | Geffard Michel | Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun |
| US5618522A (en) * | 1995-01-20 | 1997-04-08 | The Procter & Gamble Company | Emulsion compositions |
| US5837224A (en) * | 1996-01-19 | 1998-11-17 | The Regents Of The University Of Michigan | Method of inhibiting photoaging of skin |
| US6015877A (en) | 1996-03-14 | 2000-01-18 | President And Fellows Of Harvard College | Compounds for inhibition of proteolysis |
| IL131352A0 (en) | 1997-02-26 | 2001-01-28 | Thyreos Corp | Drug screen targeting lipoprotein-membrane anchorage |
| US6414037B1 (en) * | 1998-01-09 | 2002-07-02 | Pharmascience | Pharmaceutical formulations of resveratrol and methods of use thereof |
| US6251882B1 (en) | 1998-06-29 | 2001-06-26 | Parker Hughes Institute | Alkyl ketones as potent anti-cancer agents |
| EP1143954B1 (en) * | 1998-12-01 | 2004-08-11 | University of Kentucky Research Foundation | Use of nicotinic acid derivatives for the treatment of dna damage in skin cells |
| US6159485A (en) | 1999-01-08 | 2000-12-12 | Yugenic Limited Partnership | N-acetyl aldosamines, n-acetylamino acids and related n-acetyl compounds and their topical use |
| AU2201500A (en) | 1999-01-13 | 2000-08-01 | Warner-Lambert Company | Benzenesulfonamide derivatives and their use as mek inhibitors |
| CA2377254C (en) | 1999-06-18 | 2009-08-18 | Thyreos Corporation | Non-malignant disease treatment with ras antagonists |
| US20020115696A1 (en) | 1999-06-18 | 2002-08-22 | Yoel Kloog | Treatment of post-angioplasty restenosis and atherosclerosis with ras antagonists |
| YU4602A (sh) * | 1999-07-22 | 2005-06-10 | Aventis Pharmaceuticals Inc. | Farmaceutske formulacije zaštićene od dejstva mikroorganizama |
| US6372793B1 (en) | 1999-08-20 | 2002-04-16 | Florida Agricultural & Mechanical University | Method for treatment of a neurological disease characterized by impaired neuromodulator function |
| US20020010128A1 (en) * | 2000-04-13 | 2002-01-24 | Parks Thomas P. | Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism |
| JP3433380B2 (ja) * | 2000-06-07 | 2003-08-04 | 株式会社スクウェア・エニックス | 球技系ゲームのプログラムを記録したコンピュータ読み取り可能な記録媒体、球技系ゲーム処理装置およびその方法 |
| AU2001296821A1 (en) * | 2000-10-12 | 2002-04-22 | Beth Israel Deaconess Medical Center, Inc. | Methods of inhibiting angiogenesis using nadph oxidase inhibitors |
| FR2816943B1 (fr) | 2000-11-22 | 2004-02-13 | Inst Nat Sante Rech Med | Derives de la biotine, leurs procedes de fabrication et leurs utilisations en tant que vecteurs |
| AU2002249913A1 (en) * | 2001-01-03 | 2002-08-12 | President And Fellows Of Harvard College | Compounds regulating cell proliferation and differentiation |
| FR2822238B1 (fr) | 2001-03-16 | 2003-08-29 | Gemac | Methode et trousse pour le suivi des maladies neurodegeneratives |
| US20020182237A1 (en) * | 2001-03-22 | 2002-12-05 | The Procter & Gamble Company | Skin care compositions containing a sugar amine |
| US7341717B2 (en) | 2001-04-13 | 2008-03-11 | Gpc Biotech Ag | Therapeutic targets for treatment of HCV infections, methods of treating HCV infections and compounds useful therefor |
| US20030180719A1 (en) | 2001-04-13 | 2003-09-25 | Thomas Herget | Human cellular protein gastrointestinal glutathione peroxidase as target for medical intervention against hepatitis C virus infections |
| JP2005505540A (ja) * | 2001-08-27 | 2005-02-24 | メディテック リサーチ リミテッド | 改善された治療プロトコール |
| US20030059450A1 (en) * | 2001-09-24 | 2003-03-27 | Maibach Howard I. | Method and topical formulation for treating skin conditions associated with aging |
| US20030124205A1 (en) * | 2001-12-28 | 2003-07-03 | Avon Products, Inc. | Topical cosmetic composition having a natural plant active ingredient and method of using same |
| US6881427B2 (en) * | 2002-01-31 | 2005-04-19 | Alticor Inc. | Topical anti-inflammatory composition containing linseed and licorice extracts |
| EP1483283A4 (en) | 2002-03-13 | 2007-04-11 | Signum Biosciences Inc | MODULATION OF PROTEIN METHYLATION AND PHOSPHOPROTEIN PHOSPHATE |
| US20030228688A1 (en) | 2002-05-31 | 2003-12-11 | Isis Pharmaceuticals Inc. | Antisense modulation of isoprenylcysteine carboxyl methyltransferase expression |
| WO2004042081A1 (de) | 2002-11-04 | 2004-05-21 | Charité-Universitätsme Dizin Berlin | Spezifische haplotypen des mdr1-gens und deren anwendung in der diagnose und therapie |
| IL154306A0 (en) | 2003-02-05 | 2003-09-17 | Rimonyx Pharmaceuticals Ltd | Pharmaceutical compositions comprising thieno [2,3-c] pyridine derivatives and use thereof |
| US20070004803A1 (en) | 2003-03-26 | 2007-01-04 | Purdue Research Foundation | Compounds and methods for use in treating neoplasia and cancer based upon inhibitors of isoprenylcysteine methyltransferase |
| US8338648B2 (en) | 2004-06-12 | 2012-12-25 | Signum Biosciences, Inc. | Topical compositions and methods for epithelial-related conditions |
| CN101039689B (zh) * | 2004-06-12 | 2013-01-30 | 西格纳姆生物科学公司 | 用于上皮相关病症的局部组合物和方法 |
| US7846915B2 (en) | 2004-10-20 | 2010-12-07 | Resverlogix Corporation | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| MX2007007103A (es) | 2004-12-13 | 2008-03-10 | Lilly Co Eli | Derivados espiro como inhibidores de lipoxigenasa. |
| WO2006102126A2 (en) | 2005-03-18 | 2006-09-28 | Duke University | Inhibitors of isoprenylcysteine carboxyl methyltransferase |
| FR2886153B1 (fr) | 2005-05-27 | 2009-04-10 | Gemac Sa | Composition destinee au traitement de la sclerose en plaques |
-
2005
- 2005-06-13 US US11/151,174 patent/US8338648B2/en not_active Expired - Lifetime
-
2006
- 2006-06-13 EP EP06773064A patent/EP1899480A4/en not_active Withdrawn
- 2006-06-13 CA CA002611500A patent/CA2611500A1/en not_active Abandoned
- 2006-06-13 WO PCT/US2006/023022 patent/WO2006135894A1/en not_active Ceased
- 2006-06-13 US US11/921,994 patent/US20090155186A1/en not_active Abandoned
- 2006-06-13 JP JP2008517028A patent/JP2008543854A/ja active Pending
-
2010
- 2010-12-15 US US12/968,800 patent/US8334413B2/en not_active Expired - Fee Related
-
2012
- 2012-12-20 US US13/722,430 patent/US20130115177A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008543854A5 (enExample) | ||
| JP2021063088A5 (enExample) | ||
| JP2010532768A5 (enExample) | ||
| JP2010077141A5 (enExample) | ||
| JP2006526590A5 (enExample) | ||
| JP2005523922A5 (enExample) | ||
| JP2013518107A5 (enExample) | ||
| JP2013508279A5 (enExample) | ||
| JP2013534248A5 (enExample) | ||
| JP2017141277A5 (enExample) | ||
| JP2005526107A5 (enExample) | ||
| JP2011528713A5 (enExample) | ||
| JP2009502743A5 (enExample) | ||
| JP2010519260A5 (enExample) | ||
| JP2009535352A5 (enExample) | ||
| JP2013542247A5 (enExample) | ||
| JP2010522756A5 (enExample) | ||
| JP2014526503A5 (enExample) | ||
| JP2020507589A5 (enExample) | ||
| JP2009530398A5 (enExample) | ||
| PE20030347A1 (es) | Composiciones farmaceuticas, kits y procedimientos que comprenden combinaciones de agonistas/antagonistas de estrogenos, estrogenos y progestinas | |
| JP2010090149A5 (enExample) | ||
| JP2003503449A5 (enExample) | ||
| JP2008534453A5 (enExample) | ||
| JP2012508256A5 (enExample) |